


Dear friends and Protagen collaborators,

Summer is here, and many of you are looking forward to the holidays. During the second quarter we continued our immuno-oncology program with the NCI (US) and the NCT (Germany) and managed to file our first patent in this field. Our transition over the last few months from autoimmune disease specialist to immuno-monitoring company (expanding our expertise into immuno-oncology) has been remarkable, and the results from over 1,000 patient samples are excellent. This holds promise towards a great future for us in this rapidly-developing and most exciting pharma market. Thus, watch this space for further news on Protagen. In the meantime, we wish you an enjoyable summer break!



Immuno-Oncology



Further to the presentation of our initial work in immuno-oncology, we can now comment on the first results from our collaborations with the NCI and NCT. It's fair to say that we achieved what we set out to: we confirmed that autoantibodies are a novel, important biomarker class in immuno-oncology, and are also able to predict immune-related adverse events (irAEs). We also observed a link between irAEs and responsiveness to therapy. We are extremely excited and will update you on our progress going forward.

Conferences & Meet us @



Last quarter, we were in Madrid for the **EULAR conference** and attended the **German Biotech Days** in Hanover, the **Immuno-Oncology World Congress** in Philadelphia, and **BioEquity** in Paris. During these events, we presented various posters and were invited for oral presentations, which demonstrates Protagen's growing reputation and recognition. In the upcoming quarter, we will attend the **Third Cri-CIMT-EATI-AACR International Cancer Immunotherapy Conference** in Frankfurt and look forward to meeting you there.

Corporate News & PR



PR and marketing activities during the last quarter focused around our SeroTag® technology and our activities in immuno-oncology. The level of attention we receive in this area is unprecedented and we plan to continue on this path. Peter wrote an 'InsideView' article that was published in **Nature**, we had our first immuno-oncology peer-reviewed paper published in **Oncotarget**, and had further articles, editorials and interviews in various journals such as **Plattform Life Sciences**, **Personalisierte Medizin** and **Drug Discovery World (DDW)**.

Quartely Update

At the beginning of the quarter we welcomed Aristotelis Nastos to our supervisory board and we concluded it with our Annual General Meeting, held in Frankfurt this year. We attended numerous conferences and received great feedback from many of you.

Our progress in immuno-oncology is closely followed by many of you and generates interest from pharma, biotech and KOLs. We now have data on 4 of the 5 commercially-available checkpoint inhibitors and on more than a dozen solid tumour entities.

The lab work remains focused on this area. Going forward, we will see NavigAID products being developed in traditional areas such as RA and Sjögren's disease, but also in immuno-oncology with an initial focus on the prediction of irAEs and overall survival.

News

Novartis and Protagen present results of the Sjögren's collaboration project at EULAR

After our successful collaboration with **Novartis**, results were presented during the recent EULAR conference in a poster titled: 'Serum Autoantibody Profiling of Primary Sjögren's Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736 (Abstr. #SAT0301)'.

[READ MORE](#)

Inova and Protagen present results of BICD2 Systemic Sclerosis Biomarker at EULAR

After the licensing of BICD2 to **Inova Dx**, Protagen and Inova together with partners in Quebec and Calgary presented results from a recent study during the EULAR conference in a poster titled: 'Clinical and Serological Association of Autoantibodies to BICD2 as a Novel Marker for Systemic Sclerosis (Abstr. #SAT0372)'.

[READ MORE](#)

Finally – Holiday Tip

Did you manage to locate those sun loungers already reserved by Germans during your holidays? In a recent survey by Urlaubstours asking Germans which nationality they least liked to encounter on holiday, a whopping 69 per cent said they couldn't stand sunbeds blocked off by a fellow countryman's towel...so you are not alone. Wishing you a relaxing summer holiday and an empty sun lounge when needed!

